SCHEMBL23698653

SCHEMBL23698653

CCCCCCCCCC(=O)OCOc1ccc([N+](=O)[O-])c2cccnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 5/20 0.48
MAPT P10636 10/20 0.47
ALDH1A1 P00352 6/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 6/20 0.47
LMNA P02545 4/20 0.47
MEN1 O00255 4/20 0.47
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 2/20 0.47
BRD4 O60885 1/20 0.47
HSP90AA1 P07900 1/20 0.47
CHRM1 P11229 1/20 0.47
DRD2 P14416 1/20 0.47
ALOX12 P18054 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23698745 1.00 CTSB (0.48) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23698711 1.00 CTSB (0.48) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23698719 0.99 CTSB (0.48) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23698778 0.94 MAPT (0.53) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23698666 0.92 MAPT (0.52) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23698658 0.91 MAPT (0.49) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL31229275 0.91 LMNA (0.53) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23715371 0.91 LMNA (0.53) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL23698779 0.89 MAPT (0.49) CTSBMAPTALDH1A1L3MBTL1MAPK1
SCHEMBL21816898 0.89 MAPT (0.56) CTSBMAPTALDH1A1L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152048-B2 Nitroxoline prodrug and use thereof JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-11-26 US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152048-B2 Nitroxoline prodrug and use thereof NOS1, NOS2, NNT CTSB 2242/4885MAPT 2243/4885ALDH1A1 706/4885
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF NOS1, NOS2, NNT CTSB 2242/4885MAPT 2243/4885ALDH1A1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.